Nidanilimab
纳诺利单抗
Report date: 2026/04/03 20:03:44
Base Information
Drug NameNidanilimab
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications +[13]
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory +[13]
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesLund University Foundation
China Registration ClassN/A
Develop Information
Active CompaniesThe University Of Texas MD Anderson Cancer CenterCantargia Ab
Inactive CompaniesN/A
Active Indications +[13]
Inactive IndicationsN/A
Other Information
ATC CodeN/A
Related LinksN/A